What is the diagnosis for a 34‑year‑old woman presenting with heat intolerance, weight loss despite increased appetite, palpitations, anxiety, insomnia, frequent bowel movements, irritability, warm moist skin, fine tremor, mild exophthalmos, diffuse non‑tender goiter, tachycardia, elevated blood pressure, suppressed TSH, elevated free T4 and free T3, and positive thyroid‑stimulating immunoglobulin (TSI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis: Graves' Disease

This patient has Graves' disease, an autoimmune hyperthyroidism characterized by suppressed TSH, elevated free T4 and T3, positive thyroid-stimulating immunoglobulin (TSI), and classic clinical features including diffuse goiter, exophthalmos, and hypermetabolic symptoms. 1


CJMM Phase 1: Recognize Cues

Four Abnormal Cues Consistent with Graves' Disease

  • Suppressed TSH with elevated free T4 and T3: This triad definitively indicates primary hyperthyroidism, where excess thyroid hormone production suppresses pituitary TSH secretion 1
  • Positive thyroid-stimulating immunoglobulin (TSI): TSI binds to TSH receptors on thyroid follicular cells, mimicking TSH action and driving autonomous thyroid hormone production independent of pituitary control 2, 3, 4
  • Diffuse, non-tender goiter with mild exophthalmos: The diffuse goiter reflects TSI-driven thyroid enlargement, while exophthalmos (eye bulging) is pathognomonic for Graves' disease, caused by autoimmune inflammation of retroorbital tissues 1
  • Tachycardia (HR 118 bpm) with warm, moist skin and fine tremor: These reflect the hypermetabolic state from excess thyroid hormone, which increases cardiac output, metabolic rate, and sympathetic nervous system activity 1

CJMM Phase 2: Analyze Cues

How Excess Thyroid Hormones Explain Clinical Features

Weight loss despite increased appetite: Thyroid hormones increase basal metabolic rate and energy expenditure, causing accelerated catabolism that outpaces caloric intake, resulting in net weight loss of 18 lb 1

Heat intolerance: Elevated thyroid hormones increase thermogenesis and metabolic heat production, making patients feel "constantly hot" and causing warm, moist skin from compensatory sweating 1

Tachycardia (HR 118 bpm): Thyroid hormones have direct chronotropic and inotropic effects on the heart, increasing heart rate, cardiac contractility, and cardiac output, which can manifest as palpitations 1

Why TSH is Suppressed

TSH suppression occurs via negative feedback: Elevated free T4 and T3 levels directly inhibit TSH secretion from the pituitary thyrotrophs, resulting in TSH levels below the detectable range (<0.03 μIU/mL) 1, 2

TSI independently stimulates the thyroid: TSI binds to TSH receptors on thyroid follicular cells, eliminating the physiologic need for TSH to maintain thyroid hormone production, which further contributes to TSH suppression 2, 3, 4


CJMM Phase 3: Prioritize Hypotheses

Most Likely Diagnosis

Graves' disease is the definitive diagnosis, confirmed by the combination of biochemical hyperthyroidism (suppressed TSH, elevated free T4 and T3), positive TSI, diffuse goiter, and exophthalmos 1

One Potential Complication if Untreated

Thyroid storm (thyrotoxic crisis) is a life-threatening complication characterized by extreme hyperthyroidism with fever, severe tachycardia (>140 bpm), altered mental status, and cardiovascular collapse, with mortality rates of 10-30% even with treatment 1

Atrial fibrillation is another critical complication, occurring in 10-25% of hyperthyroid patients, with risk increasing 5-fold in those with suppressed TSH, particularly dangerous in this 34-year-old woman due to stroke risk 1, 5

Priority Concern at This Time

Tachycardia (HR 118 bpm) with elevated blood pressure (142/78 mmHg) is the priority concern, as sustained tachycardia increases risk for atrial fibrillation, heart failure, and cardiovascular decompensation, requiring immediate beta-blocker therapy 1, 6


CJMM Phase 4: Generate Solutions

Two Priority Nursing Interventions

Administer beta-blocker therapy immediately: Non-selective beta-blockers (preferably propranolol 20-40 mg every 6-8 hours) control tachycardia, tremor, anxiety, and other hyperadrenergic symptoms by blocking sympathetic nervous system effects 6, 7

Monitor vital signs every 4 hours: Track heart rate, blood pressure, temperature, and respiratory rate to detect early signs of thyroid storm (fever >38.5°C, HR >140 bpm, altered mental status) or cardiovascular decompensation 1, 6

Anticipated Medications

Methimazole (thionamide antithyroid drug): Initial dose 15-30 mg daily in divided doses, which inhibits thyroid peroxidase enzyme and blocks thyroid hormone synthesis, with expected normalization of thyroid function in 4-8 weeks 3, 4, 8

Propranolol (non-selective beta-blocker): 20-40 mg every 6-8 hours, providing rapid symptomatic relief of tachycardia, tremor, anxiety, and heat intolerance within hours, while also inhibiting peripheral T4-to-T3 conversion 6, 7

Required Medication Monitoring

For methimazole: Check complete blood count (CBC) with differential at baseline and if fever or sore throat develops, as agranulocytosis occurs in 0.2-0.5% of patients, typically within the first 3 months of therapy 3, 8

For methimazole: Monitor liver function tests (AST, ALT, bilirubin) at baseline and if symptoms of hepatotoxicity develop (jaundice, dark urine, abdominal pain), as hepatotoxicity occurs in <1% of patients 3, 8

For both medications: Recheck TSH and free T4 every 4-6 weeks during dose titration, targeting normalization of free T4 first (TSH may remain suppressed for months despite euthyroidism) 5, 3, 4


CJMM Phase 5: Take Action

Immediate Nursing Actions in Clinic

Obtain 12-lead ECG immediately: Screen for atrial fibrillation, atrial flutter, or other arrhythmias, as hyperthyroidism increases risk 5-fold, particularly with HR 118 bpm and suppressed TSH 1, 5

Initiate beta-blocker therapy: Administer propranolol 20-40 mg orally immediately to control tachycardia and hyperadrenergic symptoms, with repeat vital signs in 1-2 hours to assess response 6, 7

Assess for thyroid storm features: Check temperature (fever >38.5°C), mental status (confusion, agitation, delirium), and cardiovascular status (HR >140 bpm, heart failure signs), as thyroid storm requires immediate hospitalization 1, 6

Refer to endocrinology urgently: Same-day or next-day endocrinology consultation is essential for initiation of methimazole therapy and long-term management planning 6, 7

Patient Education Initiated Today

Explain Graves' disease diagnosis: "Your immune system is producing antibodies (TSI) that overstimulate your thyroid gland, causing it to produce too much thyroid hormone, which explains your symptoms of weight loss, palpitations, anxiety, and heat intolerance" 1, 2

Discuss treatment plan: "You will start methimazole to block thyroid hormone production (takes 4-8 weeks to work) and propranolol for immediate symptom relief (works within hours), with close monitoring of blood counts and liver function" 3, 4, 8

Warn about agranulocytosis: "If you develop fever, sore throat, or mouth sores while on methimazole, stop the medication immediately and seek urgent medical attention, as this may indicate a serious drop in white blood cells" 3, 8

Emphasize medication adherence: "Take propranolol every 6-8 hours as prescribed, even if you feel better, as abrupt discontinuation can cause rebound tachycardia and worsening symptoms" 6, 7

Discuss pregnancy planning: "If you are planning pregnancy, inform your endocrinologist immediately, as methimazole is contraindicated in the first trimester due to teratogenic risk, and propylthiouracil would be preferred" 5


CJMM Phase 6: Evaluate Outcomes

Findings Indicating Effective Treatment

Normalization of free T4 and T3 levels: Free T4 returning to reference range (0.72-1.74 ng/dL) within 4-8 weeks indicates adequate methimazole dosing, though TSH may remain suppressed for months 5, 3, 4

Heart rate normalization: HR decreasing to 60-100 bpm within days to weeks indicates effective beta-blocker therapy and improving thyroid status 6, 7

Resolution of hypermetabolic symptoms: Weight stabilization, improved sleep, reduced anxiety, and resolution of heat intolerance within 4-8 weeks indicate clinical euthyroidism 1, 6

TSI levels declining: Decreasing TSI titers over 6-12 months suggest disease remission, though TSI may persist for years despite clinical euthyroidism 2, 3, 4

Symptoms Requiring Urgent Reevaluation

Fever with sore throat or mouth sores: Suggests agranulocytosis from methimazole, requiring immediate CBC and discontinuation of methimazole if absolute neutrophil count <1000/μL 3, 8

Jaundice, dark urine, or right upper quadrant pain: Indicates methimazole-induced hepatotoxicity, requiring immediate liver function tests and discontinuation if AST/ALT >3× upper limit of normal 3, 8

Fever >38.5°C with altered mental status or HR >140 bpm: Suggests thyroid storm, requiring immediate hospitalization, IV beta-blockers, high-dose antithyroid drugs, corticosteroids, and supportive care 1, 6

New-onset palpitations, chest pain, or dyspnea: May indicate atrial fibrillation or heart failure, requiring urgent ECG and cardiology evaluation 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Serum thyrotropin in Graves' disease: a more reliable index of circulating thyroid-stimulating immunoglobulin level than thyroid function?

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2007

Research

Changes in thyroid-stimulating immunoglobulins during antithyroid therapy.

The Journal of clinical endocrinology and metabolism, 1979

Guideline

Initial Treatment for Elevated TSH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Management of Thyroiditis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Thyrotoxic Periodic Paralysis Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

Why do free T4 (thyroxine) levels normalize before Thyroid Stimulating Hormone (TSH) levels in patients treated with methimazole (Tapazole) for hyperthyroidism?
What is the treatment for a patient with a Thyroid Stimulating Immunoglobulin (TSI) level of 170, indicative of Graves' disease and hyperthyroidism?
What are the recommended laboratory tests for a Graves' disease diagnosis?
What is the management plan for a patient with a free T4 (thyroxine) level of 9.50 pmol/L while on methimazole (antithyroid medication) for hyperthyroidism?
What is the next step for a 7th month pregnant lady with hyperthyroidism on methimazole (antithyroid medication) with a Thyroid-Stimulating Hormone (TSH) level of 1.5 and Free Thyroxine (T4) level of 8.5?
Should a patient with a pancreatic cystic lesion undergo endoscopic ultrasound (EUS) with fine‑needle aspiration (FNA) for further characterization?
What is the recommended first-line antibiotic regimen for acute lactational mastitis in an otherwise healthy postpartum woman?
What are the diagnostic criteria (fasting plasma glucose diagnostic level, 2‑hour oral glucose tolerance test diagnostic level, HbA1c diagnostic level) for type 2 diabetes and the recommended screening guidelines for adults?
In an 82‑year‑old woman on levothyroxine and clopidogrel (Plavix) with marked microcytic anemia (RBC 3.12 ×10⁶/µL, hemoglobin 9.3 g/dL, hematocrit 27.1 %, mean corpuscular volume 27.1 fL, red cell distribution width 18.5 %) and no overt bleeding, what is the most likely cause and how should it be evaluated and managed?
What is neuroinflammation?
Does discontinuation of Verzenio (abemaciclib) cause joint inflammation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.